Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 302Parkinson Disease 4, Autosomal Dominant Lewy Body 180Melanoma 166Neoplasms 133Squamous Cell Carcinoma of Head and Neck 126Neoplasm Metastasis 98Colorectal Neoplasms 96Carcinoma, Renal Cell 80Triple Negative Breast Neoplasms 75Head and Neck Neoplasms 72Stomach Neoplasms 70Lung Neoplasms 68Breast Neoplasms 60Ovarian Neoplasms 56Carcinoma, Transitional Cell 51Uterine Cervical Neoplasms 44Endometrial Neoplasms 44Pancreatic Neoplasms 43Urinary Bladder Neoplasms 40Esophageal Neoplasms 40Carcinoma, Hepatocellular 37Small Cell Lung Carcinoma 30Cholangiocarcinoma 24Prostatic Neoplasms 22Carcinoma 22Lymphoma 20Carcinoma, Squamous Cell 20Recurrence 17Sarcoma 16Esophageal Squamous Cell Carcinoma 16

Interventions

Dexamethasone 17Bortezomib 11pomalidomide 10carfilzomib 6Lenalidomide 4imetelstat 3fludarabine 3daratumumab 3Standard of Care 3Panobinostat 3venetoclax 2siltuximab 2elotuzumab 2Cyclophosphamide 2Arsenic Trioxide 2spartalizumab 1shark cartilage extract 1selinexor 1saracatinib 1ricolinostat 1resiquimod 1poly ICLC 1plitidepsin 1pembrolizumab 1pazopanib 1motexafin gadolinium 1marizomib 1liposomal doxorubicin 1lestaurtinib 1isatuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms, Plasma Cell × pembrolizumab × Clear all
NCT04354246 2026-05-12

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

Compugen Ltd

Phase 1 Completed
94 enrolled
GastrointestinalGynecologicHead & NeckPlasma cellThoracic

Squamous Cell Carcinoma of Head and Neck, Colonic Neoplasms, Lung Neoplasms, Multiple Myeloma, Ovarian Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡